Drug · CHEMBL110
BENZNIDAZOLE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BENZNIDAZOLE. Drugs and targets, record CHEMBL110. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL110
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Benznidazol, Benznidazolum, Benzonidazol, NSC-299972, RO 07-1051, RO-07-1051, RO-7-1051, Radanil, Rochagan
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 4 diseases, from ATC, DailyMed, FDA and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| American trypanosomiasis | Approval | DailyMed, FDA and TTD | 20 | 17 | https://conductscience.org/library/drugs?q=EFO_0008559 |
| Chagas cardiomyopathy | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005491 |
| trypanosomiasis | Approval | ATC and TTD | 2 | 0 | https://conductscience.org/library/drugs?q=MONDO_0000940 |
| leishmaniasis | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0011989 |
Source Open Targets
Trials22
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01377480 | A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) | Phase 2 | 120 | 2015-08-10 | benznidazole | Its name | ClinicalTrials.gov |
| NCT00123916 | BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease | Phase 3 | 2,854 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT02386358 | Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial | Phase 3 | 910 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT02369978 | CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) | Phase 2/3 | 500 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT03981523 | New Therapies and Biomarkers for Chagas Infection | Phase 2 | 450 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT04897516 | Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease | Phase 3 | 300 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT04984616 | Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease | Phase 2 | 300 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT03191162 | Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. | Phase 2 | 238 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT01489228 | Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease | Phase 2 | 230 | benznidazole | Its name | ClinicalTrials.gov | |
| NCT01678599 | Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease | Phase 4 | 220 | benznidazole | Its name | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials31
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL110
GET https://conductscience.org/api/drugs/v1/CHEMBL110/trials?page=2